For patients living with diabetic peripheral neuropathy, a small blister or pressure sore on the foot can spiral into a chronic wound that refuses to heal. These neuropathic foot ulcers represent one of the most common complications of diabetes, often leading to infection, hospitalization, and ultimately amputation. While hyperbaric oxygen therapy (HBOT) has long been recognized as an adjunctive treatment for recalcitrant diabetic wounds, researchers continue exploring how to enhance its effectiveness. A new randomized controlled trial from Egypt suggests that pairing HBOT with polarized light therapy may offer synergistic benefits that neither modality achieves alone.
The Challenge of Neuropathic Ulcers
Peripheral neuropathy affects approximately 50% of adults with diabetes, gradually destroying the nerves that carry pain signals from the feet. Without protective sensation, patients may walk on injuries for days without noticing, allowing minor trauma to deepen into full-thickness ulcers. Compounding the problem, diabetes also damages small blood vessels, reducing oxygen delivery to tissues precisely when healing demands it most.
Standard wound care—debridement, offloading, infection control, and moist dressings—resolves many ulcers within weeks. Yet approximately 20% remain unhealed after 12 weeks, entering the category of “chronic” wounds that place patients at escalating risk. For these stubborn cases, clinicians have turned to adjunctive therapies including HBOT, which floods compromised tissues with oxygen to stimulate angiogenesis, collagen synthesis, and bacterial killing.
A Novel Combination: Oxygen Meets Light
Published July 6, 2026, in the American Journal of Physical Medicine & Rehabilitation, the Egyptian study represents the first randomized controlled trial examining HBOT combined with polarized light therapy (PLT) specifically for neuropathic foot ulcers. The research team, based at Cairo University and Ain Shams University, recruited forty patients aged 55 to 70 with established diabetic peripheral neuropathy and active foot ulcers.
Participants were randomized into two parallel groups. The experimental group received hyperbaric oxygen therapy at 2.0 atmospheres absolute (ATA) for 90 minutes, followed immediately by polarized light therapy applied directly to the wound. The control group received standard wound care alone. Both groups were treated over four weeks, with outcomes assessed at baseline, two weeks, and four weeks.
Polarized light therapy, also known as photobiomodulation, uses specific wavelengths of light to stimulate cellular metabolism. Unlike laser therapy, which delivers concentrated coherent light, PLT uses polarized but non-coherent light that penetrates tissue to depths of approximately 2 centimeters. The proposed mechanisms include enhanced mitochondrial ATP production, modulation of inflammatory cytokines, and stimulation of fibroblast proliferation—complementary effects to the angiogenic and bactericidal actions of HBOT.
Measurable Improvements in Wound Healing and Neuropathy
The results, measured across three primary endpoints, demonstrated clear advantages for the combination therapy. Ulcer volume decreased significantly more in the HBOT-plus-PLT group compared to controls, with the gap widening between the two-week and four-week assessments. Transcutaneous oxygen tension (TcPO2), which measures oxygen delivery at the tissue level, showed substantial improvement in the experimental group—suggesting that the combined intervention genuinely enhanced local perfusion rather than merely masking symptoms.
Perhaps most intriguingly, the Michigan Neuropathy Questionnaire scores, which assess subjective symptoms and clinical signs of peripheral neuropathy, also favored the combination group. This finding hints that the benefits may extend beyond wound closure to potentially improve the underlying neuropathy itself, though the study duration was too short to confirm lasting neurological changes.
Context: Where This Fits in the Evidence Landscape
The U.S. Food and Drug Administration has cleared HBOT for “certain non-healing diabetic wounds” since the early 2000s, based on evidence that the therapy can reduce amputation rates in selected patients. However, the FDA explicitly warns that HBOT is not approved for general wellness, anti-aging, or the majority of conditions marketed by commercial hyperbaric facilities. The 2025 safety letter from the FDA further emphasized fire risks and the importance of proper chamber protocols—cautions that apply regardless of whether HBOT is delivered alone or combined with other modalities.
The Cochrane review of HBOT for chronic wounds, last updated in 2015, concluded that hyperbaric oxygen “may improve short-term healing” of diabetic foot ulcers but noted that the evidence for long-term benefits remained uncertain. Subsequent trials have generally supported adjunctive HBOT for Wagner Grade 3 and 4 ulcers, particularly when ischemia limits healing potential. The Egyptian study adds a new dimension by testing whether photobiomodulation can amplify these effects—a question that previous research had explored only in animal models or uncontrolled case series.
Limitations and Unanswered Questions
As with any single-center trial involving forty patients, the findings require replication before changing clinical practice. The study population was relatively homogeneous—older adults with established diabetes—leaving open questions about whether younger patients or those with milder neuropathy would experience similar benefits. The four-week follow-up, while practical for a pilot study, cannot capture the long-term durability of wound closure or the trajectory of neuropathy symptoms.
The optimal sequencing and timing of the two interventions also remain unclear. The Egyptian protocol delivered PLT immediately after HBOT sessions, but whether this timing maximizes synergy, or whether simultaneous application would prove superior (or inferior), awaits further investigation. Similarly, the study used a specific light wavelength and intensity; different photobiomodulation parameters might yield different results.
Implications for Patients and Clinicians
For wound care specialists, the trial offers a promising signal that combination therapy may outperform monotherapy in recalcitrant cases. Patients with neuropathic foot ulcers that have failed standard care now have additional evidence to discuss with their providers—though access to both HBOT and PLT varies widely by region and insurance coverage. Medicare’s National Coverage Determination 20.29 reimburses HBOT for diabetic foot ulcers meeting specific criteria, but polarized light therapy remains inconsistently covered, potentially creating out-of-pocket costs for patients interested in the combined approach.
The study also reinforces the importance of addressing peripheral neuropathy as more than just a pain syndrome. By demonstrating measurable improvements in both wound healing and neuropathy scores, the research suggests that effective interventions may simultaneously target multiple aspects of diabetic foot pathology—ulceration, ischemia, and nerve dysfunction—rather than treating each in isolation.
The Bottom Line
Hyperbaric oxygen therapy has earned its place in the armamentarium against diabetic foot ulcers, but the quest for better outcomes continues. The Egyptian randomized trial provides early evidence that adding polarized light therapy to HBOT may enhance tissue oxygenation, accelerate wound closure, and potentially improve neuropathy symptoms. While larger, longer studies are needed to confirm these benefits and establish cost-effectiveness, the combination represents a logical next step in the evolution of adjunctive wound care—one that respects the FDA’s cleared indications while pushing the boundaries of what HBOT can achieve when paired with complementary technologies.
For now, patients with stubborn neuropathic ulcers should seek care at accredited wound centers where evidence-based protocols, including HBOT when appropriate, are combined with meticulous attention to offloading, glucose control, and infection prevention. The light-oxygen combination may not be universally available, but the underlying principles—maximizing tissue oxygenation and supporting cellular repair—remain the foundation of healing for these challenging wounds.
Sources
- Fahmy et al. — Hyperbaric Oxygen Therapy Combined with Polarized Light Therapy on Neuropathic Foot Ulcer: A Randomized Controlled Study (American Journal of Physical Medicine & Rehabilitation, 2026)
- FDA — Hyperbaric Oxygen Therapy: Get the Facts
- FDA — Follow Instructions for Safe Use of HBOT Devices (2025 Safety Letter)
- Cochrane Review — Hyperbaric oxygen therapy for chronic wounds (Kranke et al., 2015)